Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808780 · ClinicalTrials.gov registry record
An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
A clinical trial of Ulcerative Colitis, sponsored by Janssen Biotech.
- Active
- Registry status
- 537
- Enrollment target
- 20
- Study locations
NCT02808780: Active study of Ulcerative Colitis, sponsored by Janssen Biotech.
NCT02808780 is a study of Ulcerative Colitis that is active but no longer recruiting, run by Janssen Biotech. The registered enrollment target is 537 participants, below the 2,053-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02808780, a study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Janssen Biotech.
- ACTIVE NOT RECRUITING
- Registry status
- 537 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to describe the long-term safety risks in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi.
Primary Outcome
Descriptive analysis of serious adverse events, adverse events of interest (including lymphoma \& other malignancies), pregnancies, and non-serious malignancies in participants less than (\<) 30 years of age will be reported.
Conditions Studied
Study Locations (20)
Florida
- - Coral Gables
- - Fort Myers
- - Lake Worth
- - Lauderdale Lakes
- - Miami
- - Tampa
California
- - Murrieta
- - Rialto
- - Ventura
Other
- - Salzburg
- - Sankt Poelten Noe
- - Vienna
Texas
- - Houston
- - San Antonio
Georgia
- - Suwanee
Illinois
- - Chicago
Ohio
- - Sylvania
Pennsylvania
- - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 537 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2027-03-11 |
What the registry record for NCT02808780 still lists
NCT02808780 is an observational study that tracks outcomes without assigning an intervention. The registered 537 participants enrollment target is mid-sized for trials with a published cap, below the 2,053-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 0 interventions.
NCT02808780 names 20 study sites across 10 states, led by Florida, California, Other.
Frequently Asked Questions
What is clinical trial NCT02808780 about?
NCT02808780 is a clinical study titled "An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis". The purpose of this study is to describe the long-term safety risks in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi.
What is the current status of trial NCT02808780?
This trial is currently active not recruiting. The enrollment target is 537 participants. The study started on 2016-12-16. Estimated completion is 2027-03-11.
What conditions does trial NCT02808780 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
Who is sponsoring clinical trial NCT02808780?
This trial is sponsored by Janssen Biotech, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02808780 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02808780's enrollment target sits among peer trials
537 20th of 122 higher than 103 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RECRUITING
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT06538038 · 538 participants
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI